
|Articles|October 1, 2012
Ongoing botulinum injections' efficacy in question
The treatment benefit of intradetrusor onabotulinumtoxinA (Botox) for urinary incontinence due to neurogenic detrusor overactivity may decline after patients have received multiple repeat injections, findings from a study by Taiwanese urologists suggest.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD
5











